S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
Log in

NASDAQ:ALDX - Aldeyra Therapeutics Stock Price, Forecast & News

$5.06
-0.12 (-2.32 %)
(As of 02/20/2020 04:00 PM ET)
Today's Range
$5.05
Now: $5.06
$5.23
50-Day Range
$5.06
MA: $5.73
$6.39
52-Week Range
$4.31
Now: $5.06
$12.79
Volume161,472 shs
Average Volume133,455 shs
Market Capitalization$141.44 million
P/E RatioN/A
Dividend YieldN/A
Beta1.31
Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALDX
CUSIPN/A
Phone781-761-4904

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.30 per share

Profitability

Net Income$-38,890,000.00

Miscellaneous

EmployeesN/A
Market Cap$141.44 million
Next Earnings Date3/13/2020 (Estimated)
OptionableOptionable

Receive ALDX News and Ratings via Email

Sign-up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter.


Aldeyra Therapeutics (NASDAQ:ALDX) Frequently Asked Questions

What is Aldeyra Therapeutics' stock symbol?

Aldeyra Therapeutics trades on the NASDAQ under the ticker symbol "ALDX."

How were Aldeyra Therapeutics' earnings last quarter?

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) issued its earnings results on Thursday, November, 7th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.55) by $0.14. View Aldeyra Therapeutics' Earnings History.

When is Aldeyra Therapeutics' next earnings date?

Aldeyra Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 13th 2020. View Earnings Estimates for Aldeyra Therapeutics.

What price target have analysts set for ALDX?

3 brokers have issued 1 year price targets for Aldeyra Therapeutics' stock. Their forecasts range from $20.00 to $38.00. On average, they expect Aldeyra Therapeutics' stock price to reach $30.33 in the next twelve months. This suggests a possible upside of 499.5% from the stock's current price. View Analyst Price Targets for Aldeyra Therapeutics.

What is the consensus analysts' recommendation for Aldeyra Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aldeyra Therapeutics.

Has Aldeyra Therapeutics been receiving favorable news coverage?

News stories about ALDX stock have been trending somewhat negative this week, according to InfoTrie. The research group scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Aldeyra Therapeutics earned a coverage optimism score of -1.9 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Aldeyra Therapeutics.

Are investors shorting Aldeyra Therapeutics?

Aldeyra Therapeutics saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 594,100 shares, an increase of 5.6% from the January 15th total of 562,500 shares. Based on an average trading volume of 301,300 shares, the days-to-cover ratio is presently 2.0 days. Approximately 2.5% of the shares of the company are sold short. View Aldeyra Therapeutics' Current Options Chain.

Who are some of Aldeyra Therapeutics' key competitors?

What other stocks do shareholders of Aldeyra Therapeutics own?

Who are Aldeyra Therapeutics' key executives?

Aldeyra Therapeutics' management team includes the folowing people:
  • Dr. Todd C. Brady, Chief Exec. Officer, Pres and Director (Age 46)
  • Mr. Stephen J. Tulipano CPA, MBA, Chief Financial Officer and Treasurer (Age 59)
  • Dr. David J. Clark M.D., M.R.C.P., A.F.P.M., Chief Medical Officer (Age 53)
  • Ms. Mary Taylor M.P.H., Sr. VP of Regulatory Affairs (Age 59)

Who are Aldeyra Therapeutics' major shareholders?

Aldeyra Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Knoll Capital Management LP (2.04%), State Street Corp (1.49%), Geode Capital Management LLC (1.18%), Woodstock Corp (0.48%), Goldman Sachs Group Inc. (0.35%) and Connor Clark & Lunn Investment Management Ltd. (0.32%). Company insiders that own Aldeyra Therapeutics stock include Ben Bronstein, David Mcmullin, Jesse I Treu, Joshua Reed, Richard Douglas and Todd C Brady. View Institutional Ownership Trends for Aldeyra Therapeutics.

Which major investors are selling Aldeyra Therapeutics stock?

ALDX stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Meeder Asset Management Inc., Bank of New York Mellon Corp and Mesirow Financial Investment Management Inc.. View Insider Buying and Selling for Aldeyra Therapeutics.

Which major investors are buying Aldeyra Therapeutics stock?

ALDX stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Stifel Financial Corp, Private Advisors LLC, Knoll Capital Management LP, Woodstock Corp, Jacobs Levy Equity Management Inc., Geode Capital Management LLC and Banco Bilbao Vizcaya Argentaria S.A.. Company insiders that have bought Aldeyra Therapeutics stock in the last two years include Ben Bronstein, David Mcmullin, Joshua Reed, Richard Douglas and Todd C Brady. View Insider Buying and Selling for Aldeyra Therapeutics.

How do I buy shares of Aldeyra Therapeutics?

Shares of ALDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Aldeyra Therapeutics' stock price today?

One share of ALDX stock can currently be purchased for approximately $5.06.

How big of a company is Aldeyra Therapeutics?

Aldeyra Therapeutics has a market capitalization of $141.44 million. The biotechnology company earns $-38,890,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis. View Additional Information About Aldeyra Therapeutics.

What is Aldeyra Therapeutics' official website?

The official website for Aldeyra Therapeutics is http://www.ampliphibio.com/.

How can I contact Aldeyra Therapeutics?

Aldeyra Therapeutics' mailing address is 131 HARTWELL AVENUE SUITE 320, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-761-4904 or via email at [email protected]


MarketBeat Community Rating for Aldeyra Therapeutics (NASDAQ ALDX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  404 (Vote Outperform)
Underperform Votes:  332 (Vote Underperform)
Total Votes:  736
MarketBeat's community ratings are surveys of what our community members think about Aldeyra Therapeutics and other stocks. Vote "Outperform" if you believe ALDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel